Cite

HARVARD Citation

    Dagogo-Jack, I. et al. (2022). Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase–Positive Lung Cancer and CNS-Specific Relapse. JCO precision oncology. p. . [Online]. 
  
Back to record